Physician profile
William B Webb
NPI 1154589968
$365.59
in general payments reported to CMS, 2019-2025
11 companies · $64.63 in 2025
The $64.63 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.59 · 2020: $63.82 · 2021: $52.87 · 2022: $14.79 · 2024: $114 · 2025: $64.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $68.04 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $56.95 | 2020-2024 | Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.62 | 2019-2021 | |
| Csl Behring | $49.17 | 2024-2025 | Kcentra |
| Abbvie INC. | $41.07 | 2025 | |
| Lilly USA, LLC | $24.22 | 2019-2020 | |
| Allergan, INC. | $20.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.79 | 2022 | |
| Glaxosmithkline, LLC. | $12.89 | 2021 | |
| Ibsa Pharma INC. | $12.19 | 2021 | |
| Rare Disease Therapeutics, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.